Tumor malignancy is closely associated with the poor prognosis in cancer patients. Thus, accurate and sensitive diagnosis for detecting the tumor malignancy is required to provide the optimal therapeutic regimen to the patients. Nuclear medical techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are non-invasive and have the potential to provide sensitive diagnoses by detecting gamma rays emitted from a radiolabeled probe injected into the body. Thus, a radiolabeled probe targeted to a biological molecule relevant to tumor malignancy can be a useful tool for detecting the malignant tumors.
Since membrane type-1 matrix metalloproteinase (MT1-MMP) is exclusively expressed in tumors and is closely associated with metastasis and invasion, MT1-MMP is a potential target of radiotracers for the evaluation of tumor malignancy. In this study, we planned to visualize MT1-MMP in vivo by a two-step pre-targeting strategy using a streptavidin (SAv)-biotin system combined with anti-MT1-MMP monoclonal immunoglobulin (IgG) (anti-MT1-MMP monoclonal antibody (mAb)). Streptavidinylated anti-MT1-MMP mAb was synthesized by reacting biotinylated anti-MT1-MMP mAb with SAv. In the pre-targeting study, FM3A mouse breast carcinomaimplanted mice were injected with anti-MT1-MMP mAb-SAv, followed 72 h later with radioiodinated biotin, ( 125 I-IBB pre-targeted with negative control IgG-SAv. In the pre-targeting study for MT1-MMP, within 1 h of tracer injection, rapid tumor uptake and abrupt clearance from the blood of radioactivity (2.22, 0.87% injected dose/g at 1 h) were observed. The tumor to blood (T/B) radioactivity ratios were significantly higher than those from mice dosed with the pre-targeting negative control (pϽ0.0001). 125 breast cancer as the target disease for investigation of the MT1-MMP probe.
MATERIALS AND METHODS

Cell Lines and Animal Models
Female C3H/He mice (5 weeks old), supplied by Japan SLC, Inc. (Hamamatsu, Japan), were housed under a 12 h light/12 h dark cycle and were given free access to a biotin-deficient diet and water. The animal experiments in this study were conducted in accordance with institutional guidelines and approved by the Kyoto University Animal Care Committee, Japan.
The mouse breast carcinoma FM3A cell line, supplied by Health Science Research Resources Bank (Osaka, Japan), was used for the preparation of tumor-bearing animal models. The cells were grown in Dulbecco's modified Eagle's medium (Nissui Pharmaceutical Co., Japan) containing 10% fetal bovine serum and were maintained in a humidified atmosphere of 5% CO 2 and 95% air at 37°C with a 10.6 h doubling time.
FM3A cells were suspended in 0.01 M phosphate buffered saline (PBS) (pH 7.4) followed by subcutaneous inoculation into the right thigh of mice (5ϫ10 6 cells/100 ml PBS/mouse). Individual tumor volumes (V ) were estimated as Vϭab 2 /2, where a is the larger diameter and b is the smaller diameter. 15) Biodistribution studies were performed 7-8 d after implantation. The tumor volume was 155Ϯ78 mm 3 . The expression of MT1-MMP in FM3A cells and tumor tissues was confirmed by western blotting and immunohistochemistry. 8) Synthesis of Biotinylated Anti-MT1-MMP mAb Anti-MT1-MMP mAb (113-5B7, Daiichi Fine Chemical Co., Japan), a purified mouse monoclonal IgG 3 to an oligopeptide, residues 319 to 333 of human MT1-MMP numbered from the signal peptide, was used for experiments after purification with a HiTrap rProtein A column (GE Healthcare, U.K.). Since the amino acid sequence of the MT1-MMP protein is highly conserved among species including mouse, rat, rabbit, and human, 16) this antibody can cross-react with mouse as well as human MT1-MMP. 17) EZ-Link ® sulfosuccinimidyl-6-(biotinamido) hexanoate (sulfo-NHS-LC-biotin) (Pierce, Inc., U.S.A.) (105 ml, 1.0 mg/ml in 0.1 M PBS (pH 7.4)) was added to a solution of anti-MT1-MMP mAb (2.4 ml, 1.0 mg/ml in 0.1 M PBS (pH 7.4)) in a molar ratio of 12 : 1. The mixture was gently stirred for 30 min at room temperature and then was purified with a diafiltration membrane (Amicon Ultra 4 (MWCO 30000), Millipore Co., U.S.A.). The mean substitution ratio for biotin molecules coupled to the antibody was determined by the EZ TM Biotin Quantitation Kit (Pierce, Inc.) using 4-hydroxyazobenzene-2Ј-carboxylic acid (HABA). The immunoreactivity of biotinylated anti-MT1-MMP mAb was measured using flow cytometry as previously described. 18) In brief, the antibody (50 mg/ml, 100 ml) (anti-MT1-MMP mAb, biotinylated anti-MT1-MMP mAb or negative control IgG 3 (sc-3880, Santa Cruz Biotechnology, Inc., U.S.A.) was added to mouse macrophage cells (RAW264.7, 2ϫ10 6 cells) and was incubated for 30 min on ice, followed by incubation with FITC-Alexa-Fluor ® 488 goat anti-mouse IgG antibody (A-11001, Molecular Probes, Inc., U.S.A.) (10 mg/ml, 100 ml) for 30 min on ice. The fluorescence level was measured using a flow cytometer (Becton Dickinson Inc., U.S.A.), and the data were analyzed using BD CellQuest Pro (BD Biosciences Inc., U.S.A.). An index of immunoreactivity for the anti-MT1-MMP mAb and biotinylated anti-MT1-MMP mAb was calculated by the following equation: median fluorescence intensity of anti-MT1-MMP mAb or biotinylated anti-MT1-MMP mAb divided by median fluorescence intensity of the negative control IgG.
Preparation and Purification of Anti-MT1-MMP mAbSAv Conjugate A solution of biotinylated anti-MT1-MMP mAb (1.93 ml, 1 mg/ml in PBS) was added to a solution of streptavidin (SAv) (2.32 mg) (Pierce, Inc.) in a 1 : 3 molar ratio. The mixture was incubated for 1 h at 37°C followed by purification twice by affinity chromatography using a HiTrap rProtein A column. The eluate containing anti-MT1-MMP mAb-SAv was concentrated with a diafiltration membrane (MWCO 30000), and the protein concentration was determined by the bicinchoninate (BCA) method. The purification was monitored by size exclusion chromatography using a 300ϫ4.6 mm i.d. TSK-Gel Super SW 3000 column (Tosoh Co., Japan) eluted with phosphate buffer (0.1 M, pH 6.8) at a flow rate of 0.3 ml/min. Comparison to molecular mass standards (Oriental Yeast Co., Japan) of the absorbance at 280 nm indicated that a peak at 9.1 min was consistent with the presence of the 210 kDa anti-MT1-MMP mAb-SAv. Anti-MT1-MMP mAb-SAv was obtained in a yield of 36%. Negative control IgG-SAv was synthesized by the same procedure as described above in 62% yield. I-IBB) was synthesized according to the synthetic procedure outlined by Foulon et al. 19) with some modifications. Briefly, to a vial containing N-succinimidyl 3-(tributylstannyl)benzoate (72.2 ml, 2 mg/ml in methanol (1% acetic acid)) were added N-chlorosuccinimide (19.8 ml, 0.5 mg/ml in methanol) and concentrated NH 4 123 I (1110 MBq) or Na 125 I (37 MBq). The vial was vortexed, and the reaction was allowed to proceed for 30 min at room temperature. The reaction was quenched by the addition of NaHSO 3 (3.2 ml, 0.72 mg/ml in water), the solvent was evaporated under a stream of nitrogen, and the residue was used directly for the next reaction. A solution of norbiotinamine · HCl (Molecular Probes, Inc.) (100 ml, 3 mg/ml in N,N-dimethylformamide : waterϭ4 : 1, pH 8.5-9.0) was added to a vial containing the 123/125 I-N-succinimidyl 3-iodobenzoate ( 123/125 I-SIB) synthesized above, and the reaction was incubated for 2 h at room temperature. The product was purified by reverse-phase high-performance liquid chromatography (HPLC) using a Cosmosil 5C 18 -AR-300 Packed Column, 150ϫ4.6 mm i.d. (Nacalai Tesque, Inc., Kyoto, Japan), eluting with acetonitrile : waterϭ25 : 75 at a flow rate of 1.0 ml/min (retention time was 18 min for 123/125 I-IBB). The radiochemical purity was determined by thin-layer chromatography on a silica gel plate with chloroform : methanolϭ6 : 1 (Rfϭ0.53) as eluent and by analytical HPLC under the same conditions as above.
Radioiodination of Biotin
123/125
I-IBB was obtained in a radiochemical yield of 21% and 39% and a radiochemical purity of more than 94% and 95%, respectively.
Synthesis of 125 I Labeled Anti-MT1-MMP mAb-SAv
Conjugation of
125 I-SIB with streptavidin was performed according to the procedure of Zalutsky and Narula 20) with slight modifications as follows: a solution of streptavidin (300 ml, 20 mg/ml in 0.15 M borate buffer (pH 8.5)) was added to the dried residue of crude 125 I-SIB (32.6 MBq). After gentle agitation for 30 min at room temperature, the radioiodinated streptavidin was applied to a diafiltration membrane to remove unbound 125 I-SIB as well as to change buffer to PBS (0.1 M, pH 7.4). To a vial containing purified 125 Istreptavidin (18.5 MBq, 2.6 ml, 1.1 mg/ml in PBS), a solution of MT1-MMP mAb-Bt (1.0 ml, 3.6 mg/ml in PBS) was added, and the reaction was incubated for 1 h at room temperature followed by purification twice by affinity chromatography using a HiTrap rProtein A column. The eluate containing 125 I-SAv-anti-MT1-MMP mAb was concentrated with a diafiltration membrane. The protein concentration was determined by the BCA method.
125
I-SAv-anti-MT1-MMP mAb was obtained in a radiochemical yield of 11% and a radiochemical purity of more than 94%.
In Vivo Biodistribution Study Mice were divided into 4 groups (nϭ3-9) for 4 or 5 time points with approximately equal distribution of tumor sizes on the day before the study. Animals were fasted for 6 h before administration of the radiopharmaceutical. Outline of the each biodistribution study is shown in Fig. 1 .
One, 6, 24, 48, and 72 h after the injection of 125 I-SAvanti-MT1-MMP mAb (90 kBq, 50 mg/100 ml in saline), the blood, heart, lung, liver, kidney, intestine, pancreas, spleen, muscle, brain, and tumor were excised, weighed, and counted for radioactivity with a NaI well-type scintillation counter (1470WIZARD, PerkinElmer Japan Co.) using the injected dose as a standard. Data were calculated as % injected dose (ID)/g of tissue and %ID/organ.
In the pre-targeting,
I-IBB (110 kBq, 100 ml in saline) was injected intravenously into mice 72 h after pre-treatment with anti-MT1-MMP mAb-SAv (50 mg/100 ml in saline). One, 3, 6 , and 24 h after the injection of 125 I-IBB, the biodistribution was evaluated as described above. The biodistribution of 125 I-IBB alone and 125 I-IBB pre-targeted with negative control IgG-SAv (50 mg/100 ml in saline) were also evaluated 1, 3, 6, and 24 h post-injection in the same manner.
In Vivo Imaging Studies The SPECT studies were performed using a SPECT-2000H-40 gamma camera (Hitachi Medical Co.). Mice (nϭ2) bearing an FM3A tumor in the right thigh received anti-MT1-MMP mAb-SAv (50 mg/100 ml in saline) via the tail vein. Three days later, 123 I-IBB (62.9 MBq/100 mL in saline) was injected followed by data acquisition as static SPECT scans (360°rotation, 30 s/step for 64 steps) using low-energy high-resolution, parallel-hole collimators (30% window, 159 keV energy peak, 128ϫ128 matrix mode, pixel size of 2.0 mm) at 3, 6, and 24 h post injection under halothan (1.5%) anesthesia. Images were reconstructed with a standard filtered back projection algorithm.
After the SPECT scans, X-ray images of the mice were obtained for an anatomical comparison using an R-mCT system (Rigaku Co.) equipped with a fixed microfocus X-ray tube and X-ray sensor. This instrument exposes a coneshaped X-ray beam on the 2D detector through the animal set on a stage. The revolving arm rotates 360°around the mouse for 17 s to acquire a full 3D computerized tomography (CT) data set.
Statistical Analysis To compare the time courses of radioactivity in the tumor, tumor to blood (T/B) and tumor to muscle (T/M) ratios among anti-MT1-MMP mAb-SAv pretargeted 125 I-IBB, negative control IgG-SAv pre-targeted 125 I-IBB and 125 I-IBB alone, two-way factorial ANOVA followed by a Tukey-Kramer test was performed. Differences at the 95% confidence level (pϽ0.05) were considered significant. 
RESULTS
Immunoreactivity of Biotinylated Anti-MT1-MMP mAb
The number of conjugated biotins per antibody was 2.2Ϯ0.5 when the reaction ratio of anti-MT1-MMP mAb and biotin was 1 : 12. The indices of immunoreactivity evaluated by the flow cytometry analyses were 5.8Ϯ0.9 and 6.1Ϯ1.0 for the biotinylated anti-MT1-MMP mAb and the intact anti-MT1-MMP mAb, respectively. The immunoreactivity of the anti-MT1-MMP mAb was not affected by the introduction of biotins into the anti-MT1-MMP mAb (greater than 90% retained).
Biodistribution Studies To determine the timing for post-administration, a biodistribution study of 125 I-SAv-anti-MT1-MMP mAb was performed first (Table 1) . Radioactivity in the tumor reached a peak at 24 h (7.69% ID/g) and gradually decreased (6.34% ID/g at 48 h and 5.78% ID/g at 72 h). The kidney and spleen showed rather high radioactivity over time (10.56, 12 .70% ID/g at 72 h, respectively). The T/B ratios increased in a time-dependent manner and reached greater than 1.0 at 72 h after injection. Therefore, taking into consideration radioactivity in the tumor and T/B ratios, an interval of 72 h was selected for the subsequent pre-targeting study.
Results of in vivo biodistribution studies of 125 I-IBB with pre-targeting using the anti-MT1-MMP mAb-SAv or negative control IgG-SAv are summarized in Tables 2 and 3 . In the pre-targeting study targeting MT1-MMP (Table 2) , 125 I-IBB was highly accumulated in the tumor at 3 h (2.36% ID/g) and a high level was maintained for 24 h after the injection (1.06% ID/g at 24 h) while blood clearance was rapid (0.47, 0.07% ID/g at 3, 24 h, respectively), resulting in high T/B ratios of 125 I-IBB early after the injection (2.55 at 1 h, 5.36 at 3 h, 7.78 at 6 h, 14.13 at 24 h). T/M ratios increased in a similar manner (3.09 at 1 h, 6.14 at 3 h, 6.99 at 6 h, 12.09 at 24 h). Other organs with the exception of the kidneys, intestine and spleen showed low radioactivity 24 h after the injection.
Radioactivity in the tumor was significantly lower (0.66%
ID/g at 24 h) in the control pre-targeting study (Table 3 ) than in the actual pre-targeting study (pϽ0.0005), and the blood clearance was slightly slower (0.08% ID/g at 24 h). T/B ratios were significantly higher with the true pre-targeting method as compared to the control pre-targeting method (pϽ0.0001) (Fig. 2) . T/M ratios were also higher with the true pre-targeting method, although these values were not significantly different between the groups. The biodistribution to other tissues, including the kidneys, intestine, spleen and liver, was similar between the groups. In the biodistribution study of 125 I-IBB alone (Table 4) , negligible accumulation in the tumor (0.15, Ͻ0.01% ID/g at 3, 24 h, respectively) and an extremely rapid blood clearance (0.33, 0.03% ID/g at 3, 24 h, respectively) were observed. T/B and T/M ratios were small over time (0.44, 0.58 at 1 h, 1592 Vol. 33, No. 9 I-IBB and the accumulation of radioactivity in the tumor was maintained for 24 h. Though the kidneys, bladder and intestine were also visualized, the radioactivity in these tissues decreased relatively quickly over time compared with that in the tumor. Chest organs such as the lungs and heart, and the liver were not visualized. The distribution of signals in each tissue was very consistent with the distribution of radioactivity observed in the in vivo biodistribution study (Table 2 ).
DISCUSSION
In this study, we developed a novel MT1-MMP imaging method based on anti-MT1-MMP mAb combined with a pretargeting strategy using a biotin-streptavidin system. The effectiveness of this pre-targeting method (streptavidinylated anti-MT1-MMP mAb and 123/125 I-IBB) was validated since significantly higher T/B ratios were achieved during the first hours after administration than had been observed in our previous study using a directly labeled antibody, 8) and SPECT imaging clearly visualized tumor tissues in vivo. It should be emphasized that in vivo imaging of MT1-MMP relevant to the malignancy of tumors was achieved in this study. Radiolabeled antibodies typically have a low rate of blood clearance, which can be a crucial pitfall for radioimmunodetection and radioimmunotherapy. To solve this problem, antibody fragments (Fab, scFv) and engineered variants (diabodies, triabodies, minibodies) have been investigated. 21) However, these techniques can cause problems such as reduced immunoreactivity of antibody derivatives and reduced delivery of radioactivity to the targeted organs. 22) On the other hand, the pre-targeting method has been investigated extensively, especially in tumor treatment, because of the selective accumulation of radioactivity to the targeted organ without a loss of antibody immunoreactivity and the high S/N ratio that can be achieved during the first hours after administration. 9) In fact, the introduction of a few biotins did not affect the immunoreactivity, and sulfo-NHS-LC-biotin with a spacer arm of 22.4 Å was used to minimize the steric effect by streptavidin. Recently, other reports have also shown that a pre-targeting method was effective for in vivo imaging of biofunctional molecules such as CD20.
11) Therefore, the pre-targeting method seems to address many of the limitations of the direct radioimaging agent approach.
In this paper, accumulated radioactivity in the tumor and T/B ratios were significantly higher in the true pre-targeting study than in the negative control pre-targeting study (ANOVA test). Thus, the accumulation of radioactivity in tumors pre-targeted with anti-MT1-MMP mAb-SAv suggests that specificity for MT1-MMP is responsible for this effect. Moreover, the tumor accumulation of 125 I-IBB in the absence of pre-targeting was not observed, which suggests the tumor accumulation of 125 I-IBB in the pre-targeting study depended on the pre-targeting antibody. As a result of rapid clearance of 125 I-IBB, the pre-targeting method achieved high T/B ratios significantly earlier than did our previously studied directly labeled anti-MT1-MMP mAb.
8) The T/B ratio obtained within 1 h with the pre-targeting method was higher than that from the directly labeled anti-MT1-MMP mAb at 48 h. Furthermore, tumor to lung and tumor to heart ratios from the pre-targeting method were 10.6 and 4.5 fold higher compared with the directly labeled anti-MT1-MMP mAb at 1 h after the injection of the radiolabeled probe. These results indicate the pre-targeting method provides clearer imaging of MT1-MMP in breast tumors during the first hours after administration.
Specific accumulation for MT1-MMP can be estimated by comparing the radioactivity in the tumor and T/B ratios in the true pre-targeting method with those in the negative control method. About 30-40% specific accumulation was achieved in this study, although 125 I-IBB accumulated in the tumor to some extent in the negative control pre-targeting study unexpectedly. This is probably caused in part by passive accumulation of the streptavidinylated antibody as a macromolecule, that is enhanced permeability and retention effect. 23) In addition, an RYD sequence contained in SAv, 24) homologous to the RGD domain, might interact with integrins expressed on the cell surface of tumors. 25) By replacing SAv with neutravidin, which lacks the RYD domain, a more specific imaging of MT1-MMP may be achieved in the future.
In the SPECT imaging study of the pre-targeting method, tumors were clearly visualized. High levels of radioactivity were also observed in the kidneys and intestine. This may be due to the high kidney uptake of pre-targeted streptavidinylated anti-MT1-MMP mAb that is dependent on the biodistribution of streptavidin itself 26) and to physiological 125 I-IBB accumulation in the intestine.
125 I-IBB also accumulated in the bladder because its molecular weight leads to glomeruli filtration. It should be stressed that chest organs such as the lungs and heart, and the liver were not visualized, which indicates the potential of this method for adequate imaging of breast tumors expressing MT1-MMP. In addition, preliminary Western blotting analysis using lysates from human breast cancer cells (MDA-MB-231) detected a high level of human MT1-MMP expression, 8) suggesting that this method may be useful in a clinical setting. We are currently investigating the effectiveness of this pre-targeting method across a variety of tumor cells that differently express MT1-MMP.
In this study, 123/125 I-labeled biotin was used to demonstrate the availability of pre-targeting method for MT1-MMP because its stability, affinity to avidin and biodistribution was well examined. 19) On the other hand, 99m
Tc generated by a 99 Mo/ 99m Tc generator on site at any time on demand is attractive for clinical use, and 99m Tc-biotin may also deserve investigation on pre-targeting methods.
Biodistribution of streptavidinylated anti-MT1-MMP antibody was examined for 1-72 h. T/B ratios increased in a time dependent manner and were highest at 72 h, which has the potential that T/B ratios may be improved at the later stage after injection, leading the high contrast images of MT1-MMP. On the other hand, sensitivity can be dependent on the absolute radioactivity of 123/125 I-IBB in the tumor tissue, which is an important indicator on molecular imaging. In this study, accumulation of streptavidinylated antibody in the tumor was decreased with time, indicating that 123/125 I-IBB was also predicted to show the lower tumor uptake at the later stage. Thus, by taking into consideration radioactivity in the tumor and T/B ratios, we adopted the protocol such that radiolabeled biotin was administered 72 h after pre-treatment with streptavidinylated antibodies, although further studies are needed for setting the optimal interval. To date, some reports have shown that clearing agents (e.g. galactosylated biotin-albumin conjugate) can readily (a few hours) remove excess streptavidinylated antibodies in the circulation via the liver without loss of biotin binding sites in the tumor, 27, 28) thus leading to a shortening of the interval needed between administration of the streptavidinylated antibody and radiolabeled biotin. In this study, we obtained the data that accumulation of streptavidinylated anti-MT1-MMP mAb was reduced after the peak at 24 h post-injection probably because of the internalization and metabolism in the tumor cells. 29) Thus, the clearing agents may enable the administration of radiolabeled biotin at the earlier time point when streptavidinylated antibody in the tumor is highly retained. This strategy will help establish an optimal protocol for sensitive MT1-MMP imaging with an aim toward clinical application.
CONCLUSION
The results clearly demonstrate the effectiveness of the pre-targeting method for imaging MT1-MMP in breast tumors with greater sensitivity and earlier post-injection analysis in comparison with the direct-radiolabeled antibody. As mentioned previously, the amino acid sequence of the MT1-MMP protein is highly conserved among species including mouse, rat, rabbit, and human; our results obtained in experiments using rodents and MT1-MMP probes may provide important information for clinical applications and may prove to be beneficial in the diagnosis of breast tumor malignancy in the clinical setting.
